| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cost of Revenue | $25K | — |
| R&D Expense | $2.0M | +30.8% |
| SG&A Expense | $2.4M | +98.2% |
| Operating Income | -$13.3M | -21.8% |
| Net Income | -$13.0M | -19.4% |
| EPS (Basic) | -$0.48 | -17.1% |
| EPS (Diluted) | -$0.48 | -17.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $8.9M | +93.9% |
| Current Assets | $9.3M | +97.1% |
| Total Assets | $13.6M | +82.6% |
| Current Liabilities | $1.8M | -41.0% |
| Total Liabilities | $1.9M | -38.7% |
| Stockholders' Equity | $11.6M | +170.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$4.3M | -80.0% |
| Capital Expenditures | $1.8M | +6486.1% |
| Investing Cash Flow | -$2.3M | -547.7% |
| Financing Cash Flow | $10.9M | +56.7% |
| Free Cash Flow | -$6.1M | -154.3% |